Open AccessGALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway
Author(s) -
Huawen Li,
Mubiao Liu,
Xue Jiang,
Ting Song,
Shuxian Feng,
Jingya Wu,
Pengfei Deng,
Xiaoyu Wang
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0883
Subject(s) - downregulation and upregulation , ovarian cancer , pi3k/akt/mtor pathway , cisplatin , cancer research , apoptosis , medicine , blot , cancer , oncology , chemotherapy , biology , biochemistry , gene
Background: Chemoresistance usually occurs in ovarian cancer. We aimed to explore the mechanisms of chemoresistance. Methods: Western blotting assay was used to detect the expression of GALNT14. Further cell function experiments were performed to investigate the effect of GALNT14 in ovarian cancer. Results: GALNT14 is significantly upregulated in ovarian cancer. Downregulation of GALNT14 significantly inhibits both apoptosis and ferroptosis of ovarian cancer cells. A further mechanism assay illustrated that downregulation of GALNT14 suppresses the activity of the mTOR pathway through modifying O-glycosylation of EGFR. Finally, an additive effect promoting cell death occurs with a combination of an mTOR inhibitor and cisplatin. Conclusion: Our study might provide a promising method to overcome cisplatin resistance for patients with ovarian cancer.